The Pentagon prescribed an unprecedented total of erectile dysfunction drugs to active military personnel in 2025, highlighting a stark contrast with the ongoing ban on gender-affirming medical care for transgender service members. According to documents obtained through a Freedom of Information Act request, more than 108,000 prescriptions for erectile dysfunction medications were dispensed to active-duty troops alone last year.
The wider military community—which includes dependents of service members and veterans—received a substantially higher volume, with over 639,000 prescriptions issued in 2025. This data underscores a significant medical expenditure on erectile dysfunction within the armed forces, occurring simultaneously with strict limitations on transgender health care services.
The U.S. Department of Defense continues to enforce policies that prohibit military clinics and insurance plans from covering gender-affirming treatments. In early 2025, defense officials formalized rules barring gender-affirming care for active service members and preventing enlistment of individuals with a history of gender dysphoria.
LGBTQ+ advocacy groups have sharply criticized what they describe as a contradictory approach. They argue that the provision of erectile dysfunction drugs—a treatment associated with affirming male sexual function—could itself be framed as a form of gender-affirming care, highlighting perceived inconsistencies in military health policy.
This directive has sparked ongoing legal challenges. One prominent case, Doe v. Department of Defense, contests the ban on gender-affirming care for military families, asserting that the policy unlawfully denies essential medical services previously accessed through military health programs. Other litigation efforts also contest the ban on transgender enlistment in the armed forces.
The debate over military healthcare policies for transgender service members continues to generate significant legal and social scrutiny, with advocates calling attention to disparities in treatment coverage within the military health system.